| |
Newsroom /
Health and Fitness
/
Healthcare
/
Type-2 Diabetes - Drug Pipeline Analysis and Market Forecasts to 2016
Type-2 Diabetes - Drug Pipeline Analysis and Market Forecasts to 2016
The type-2 Diabetes Market is forecast to Grow at a Healthy Rate between 2009 and 2016
Hyderabad,
AP,
India
(prbd.net)
03/02/2010
"Type-2 Diabetes - Drug Pipeline Analysis and Market Forecasts to 2016"
GlobalData estimated the global type-2 diabetes market, in 2009, at $21.9 billion indicating a compound annual growth rate (CAGR) of 11.2% between 2001 and 2009. The growth in the market is mainly attributed to the alarming rise in the prevalence of diabetes in the US and major European countries. By 2016, the market is forecast to record $33.7 billion with a CAGR of 6.4% between 2009 and 2016. The major drivers for the future growth of the type-2 diabetes market are ageing population, prevalence rates and launch of new first-in-class drugs.
GlobalData’s analysis indicates that the current competition in the type-2 diabetes market is strong. The market in 2009 is led by Actos, Januvia, Byetta and Lantus. Until 2007, Avandia dominated the type-2 diabetes market along with Actos. However, recent disclosures of the drug’s probable cardiovascular side effects affected its sales. Biguanides, especially Metformin, were the largest selling antidiabetic drugs in terms of sales volume in 2009. Following biguanides were glitazones, sulfonylureas and insulin analogues. The major players in the type-2 diabetes market include Takeda Pharmaceuticals, Merck & Co., and Novo Nordisk.
GlobalData’s analysis shows that the currently available treatment options are meeting the desired efficacy levels. However, these drugs potentially lack effective safety profile. This is the major unmet need in the type-2 diabetes market. For example, Avandia (rosiglitazone) was found to increase the probability of heart risks and other heart related problems in type-2 diabetes patients. Similarly, the US FDA revised the safety information of Byetta (exenatide) by adding information about possible kidney function problems, including kidney failure.
GlobalData’s analysis demonstrates that there are over 177 molecules in various stages of the pipeline. Victoza, one of the promising drugs, is awaiting the US FDA approval. The drug is already approved by EMEA in 2009. The late stage pipeline includes few first-in-class and promising drugs such as dapagliflozin and D-Tagatose. These molecules differ from others as their site of action is different from that of the already marketed products. The major new classes of drugs include SGLT-2 inhibitors, 11β HSD inhibitors, CCR2 antagonists, selective inhibitors of fructose 1,6-bisphosphatase, immune modulators, cortisol synthesis Inhibitors, interleukin-1β antagonists, gastrin-releasing peptide (GRP) receptor agonists, GPR 119 agonists,TLR-4 receptor agonists, FXR antagonists and antisense drugs targeting glucagon receptor. Majority of the pipeline is inundated with me-too drugs such as DPP-4 inhibitors, PPAR agonists, and GLP-1 agonists. Once these drugs enter the market, intense price war is expected to arise since these drugs will share the same patient base, which their first generation products catered to.
GlobalData, the industry analysis specialist, has released its new report, “Type-2 Diabetes - Drug Pipeline Analysis and Market Forecasts to 2016”. The report is an essential source of information and analysis on the global type-2 diabetes therapeutics market. The report identifies the key trends shaping and driving the global type-2 diabetes therapeutics market. The report also provides insight into the prevalent competitive landscape and the emerging players expected to change the market position of the existing market leaders. Most importantly, the report provides valuable insight into the pipeline products within the global type-2 diabetes therapeutics sector.
visit our report store: http://www.globaldata.com/reportstore
About
GlobalData is a global market intelligence services company providing information research and analysis products and services.
|